Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...

Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical ...

Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates ...

Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an ...

The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...